Press release
MHRA Exclusive Speaker Interview Released and ImmuneBiotech AB CEO Announced as Latest Speaker ahead of Immuno-Oncology 2018
Immuno-Oncology 2018
There’s just over 1 week to go until SMi’s Immuno-Oncology conference on 26th – 27th September 2018 in London, UK (http://www.immuno-oncology-conference.com/openpr), set to bring together an unrivalled gathering of industry leaders and scientific pioneers to explore the potential of targeted immuno-therapies.
A new session on day one has recently been announced, with Shahram Lavasani, the CEO of ImmuneBiotech AB presenting on “Could the Microbiome Boost Cancer Immunotherapy?”. Shahram will be providing his expertise and experience on the understanding of the dynamics and function of the human microbiome in health and disease, dysbiosis and cancer therapy, and microbial interventions.
In the run up to the two-day conference, SMi also caught up with Dr Andrew Exley, a Medical Assessor, for an exclusive interview to discuss his role in the MHRA, the biggest challenges and innovations in Immuno-Oncology, and what he hopes to gain from this year's meeting.
Interview Snapshot:
Q. What would you say is the biggest barrier to implementation of Immuno-Oncological therapies in common treatment plans?
A. The biggest barriers to implementation of Immuno-Oncological therapies into common treatment plans are the identification, validation and interpretation of clinically meaningful biomarkers, surrogate endpoints and clinical trial goals. Overcoming these clinical barriers has a critical role in addressing the economic concerns about Immuno-Oncology therapies.
Q. What do you think has been the greatest innovation within Immuno-Oncology over the last year or two? Where do you see Immuno-Oncology leading us over the next few years?
A. The potential and pitfalls within Immuno-Oncology are exemplified by recent developments in checkpoint blockade and CAR-T cells. Progress in targeting and optimising these therapies is anticipated.
Dr Exley is a Medical Assessor in the Biologicals and Biotechnology Unit within the Licensing Division of the MHRA in London. He provides bench to bedside expertise in immunology and regulatory affairs including diagnostics, biomarkers, and clinical endpoints, from a background of extensive experience as a consultant immunologist.
Dr Exley will also be speaking and presenting at this year's conference on "Generating Symbiosis with Regulatory Affairs in Immuno-Oncology". The full interview is now available to download on the event website’s download section at http://www.immuno-oncology-conference.com/openpr
2018 Event Highlights:
• Learn about targeting immune checkpoints with Humabody VH Therapeutics
• Discover advances in durable disease control with Keytruda as an anti-cancer therapy
• Discuss the tumour mutation burden and the potential of its use as an indication of treatment choice
• Develop an understanding of unwanted immunogenicity and functionality testing of immuno-oncology drugs
• Gain insight into new techniques, such as emerging applications of liquid biopsies
Visit the website to find out more, download the latest brochure, full speaker line-up and other exclusive content, and register your place: http://www.immuno-oncology-conference.com/openpr
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
SMi Group
1 Westminster Bridge Rd, South Bank, London SE1 7XW
Maria Mandic
mmandic@smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MHRA Exclusive Speaker Interview Released and ImmuneBiotech AB CEO Announced as Latest Speaker ahead of Immuno-Oncology 2018 here
News-ID: 1249439 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for MHRA
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conferenc …
SMi Reports: Industry leaders MHRA, Pfizer, Autolus, Tusk Therapeutics, KCL, Boehringer Ingelheim and more are amongst the latest organisations to register for Immuno-Oncology 2018 (http://www.immuno-oncology-conference.com/openpr)
There’s just 2 weeks until SMi’s Immuno-Oncology conference commences in London on the 26th and 27th September. With limited places left, interested attendees are urged to book soon to avoid missing out on joining an international gathering of immuno-therapy experts at this highly-anticipated conference.
Recent Confirmed Attendees…
Talks from the MHRA, Innovate UK, Plasticell and more
The lengthening shadow of increase in health spending in the coming years is sharpening the minds of legislators, regulators and payers alike. The growing time-to-market, the rising costs in development of novel medicines, as well as the more basic drive to be ‘ahead of the game’, forces the industry and the legislators to rethink basic postulates of drug development.
The global regulatory environment is undergoing major reshape, allowing patients early access…
MHRA & FDA to explore In Vitro Diagnostics regulations in the EU & USA
The 3rd In Vitro Diagnostics conference for SMi Group will take place in London on the 14th & 15th June 2017.
Aimed at Managers/Heads and Directors of Regulatory Affairs, In Vitro Diagnostics, Clinical Affairs and Quality Assurance, IVDs 2017 will provide regulatory updates and key industry feedback from leading IVD manufacturers within this complex and ever-changing landscape.
Through a series of presentations from handpicked industry experts and Notified Bodies, the 2017…
Attendee List Released for Superbugs 2017 Featuring FDA, GSK, MHRA, Merck and Ab …
With just 4 weeks to go, an attendee list featuring an international audience of AMR experts and scientific pioneers has been released ahead of SMi's long running 19th annual summit on Superbugs & Superdrugs.
The industry calendar highlight on antibiotic resistance will provide a platform for attendee's to network, exchange novel solutions and consolidate current strategy.
Notable sessions on the agenda include:
1. Guidance on common governing pitfalls presented by the FDA.
2. Strategies to…
Attendee List Released Ahead of RNA Therapeutics Industry Summit Featuring MHRA, …
SMi Group have released an attendee list two weeks ahead of the 8th annual conference on RNA Therapeutics which is set to take place in Central London on 22nd & 23rd February.
This year’s show has attracted a truly global audience of scientific pioneers and senior industry thought leaders involved in targeted drug delivery systems from Australia, Belgium, Denmark, Germany, Ireland, Israel, Italy, Japan, Netherlands, Switzerland, Ukraine, United Kingdom and USA.…
MHRA to advise on mHealth app initiative for pharmacovigilance
WEB-RADR Project Lead Phil Tregunno joins speaker lineup for the 9th Social Media in the Pharmaceutical Industry in London
SMi has confirmed that Phil Tregunno, the MHRA’s Signal Management Unit Manager and WEB-RADR Project Lead, will be speaking at the 9th Social Media in the Pharmaceutical Industry conference. The event takes place on the 18th and 19th of January 2017 in London.
More companies continue to improve initiatives for pharmacovigilance. Recently, the…
